Integrated Summary of Safety – Complexities, Communication and Completion

1 minute read

Case Studies

Published: January 25th, 2021

Phastar was contracted to assist a pharmaceutical company with the conversion of 16 legacy studies to SDTM (2 SDTM “Like” phase II studies, 14 Legacy Phase I studies) and with the pooling and reporting activities of their Integrated Summary of Safety (ISS) for a regulatory submission. It has been quite a challenging project but one of the most exciting due to its complexity.

Complete the form below to read the full case study

Related articles

Translating Real-World Data into Commercial Success with Outcome Modelling 
Case Studies

Translating Real-World Data into Commercial Success with Outcome Modelling 

July 13th, 2026 1 minute read

Demonstrating real-world value is critical for securing pricing and market access, but bridging the gap between clini...

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 
Case Studies

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

July 13th, 2026 1 minute read

Biopharma organizations have access to vast amounts of real-world data, but extracting meaningful, actionable insight...

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer
Case Studies

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

July 13th, 2026 1 minute read

Demonstrating short-term efficacy is no longer enough, regulators increasingly require a clear understanding of long-...